PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis

Published:2022-06-10 Issue:1 Volume:28 Page:149-156
ISSN:1573-7322
Container-title:Heart Failure Reviews
language:en
Short-container-title:Heart Fail Rev

Author:

Jennings Douglas L.^ORCID,Sultan Lina,Mingov Jennifer,Choe Jason,Latif Farhana,Restaino Susan,Clerkin Kevin,Habal Marlena V.,Colombo Paolo C.,Yuzefpulskaya Melana,Sayer Gabriel,Uriel Nir,Baker William L.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10741-022-10255-5.pdf

Reference24 articles.

1. Chih S, Chong AY, Mielniczuk LM, Bhatt DL, Beanlands RS (2016) Allograft vasculopathy: the achilles’ heel of heart transplantation. J Am Coll Cardiol 68:80–91

2. Costanzo MR, Dipchand A, Starling R et al (2010) International society of heart and lung transplantation guidelines. The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant 29:914–956

3. Harris J, Teuteberg J, Shullo M (2018) Optimal low-density lipoprotein concentration for cardiac allograft vasculopathy prevention. Clin Transplant 32:e13248

4. Karatasakis A, Danek BA, Karacsonyi J et al (2017) Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc 6:e006910

5. Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipoprotein (a) and lipid-lowering treatment from the perspective of a cardiac surgeon. An impact on the prognosis in patients with aortic valve replacement and after heart transplantation;International Journal of Cardiology Cardiovascular Risk and Prevention;2024-09

2. Treatment of Hyperlipidemia With Alirocumab in a Liver Transplant Recipient With Poor Blood Lipid Control: Case Report;Transplantation Proceedings;2024-06

3. Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients;JACC: Heart Failure;2024-06

4. Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review);International Journal of Molecular Medicine;2024-05-10

5. Features of lipid-lowering therapy in liver transplant recipients;Cardiovascular Therapy and Prevention;2024-02-08